menu search

SWTX / SpringWorks (SWTX) Down Despite Desmoid Tumors Study Meeting Goal

SpringWorks (SWTX) Down Despite Desmoid Tumors Study Meeting Goal
SpringWorks' (SWTX) phase III study evaluating its investigational candidate, nirogacestat, in adult patients with progressing desmoid tumors, meets primary and key secondary endpoints. Read More
Posted: May 25 2022, 13:48
Author Name: Zacks Investment Research
Views: 091957

SWTX News  

SpringWorks Therapeutics: FDA Decision Date Ahead

By Seeking Alpha
July 12, 2023

SpringWorks Therapeutics: FDA Decision Date Ahead

Today we revisit SpringWorks Therapeutics, Inc. for the first time in nearly a year. The company's primary drug asset is on the cusp of garnering Spri more_horizontal

US FDA delays decision on SpringWorks Therapeutics' tumor treatment

By Reuters
June 5, 2023

US FDA delays decision on SpringWorks Therapeutics' tumor treatment

The U.S. Food and Drug Administration (FDA) has extended its decision for SpringWorks Therapeutics Inc's tumor treatment by three months as the health more_horizontal

SpringWorks Therapeutics: Pfizer Offshoot With Interesting Pipeline

By Seeking Alpha
April 14, 2023

SpringWorks Therapeutics: Pfizer Offshoot With Interesting Pipeline

SpringWorks Therapeutics: Pfizer Offshoot With Interesting Pipeline more_horizontal

SpringWorks Therapeutics Shares Jump On HC Wainwright Bullish Pitch

By Benzinga
June 13, 2022

SpringWorks Therapeutics Shares Jump On HC Wainwright Bullish Pitch

HC Wainwright points out that investors are enthusiastic about SpringWorks Therapeutics Inc (NASDAQ: SWTX) nirogacestat clinical profile for desmoi more_horizontal

SpringWorks Therapeutics to Present Progress Across the Company's Targeted Oncology Portfolio at Virtual R&D Day

By GlobeNewsWire
June 10, 2022

SpringWorks Therapeutics to Present Progress Across the Company's Targeted Oncology Portfolio at Virtual R&D Day

-- NDA filing for Nirogacestat in Desmoid Tumors, Which Will Be Reviewed Under the FDA's Real-Time Oncology Review (RTOR) Program, Expected in Second more_horizontal

Here is why SpringWorks Therapeutics jumped 20%

By Invezz
May 27, 2022

Here is why SpringWorks Therapeutics jumped 20%

SpringWorks Therapeutics Inc. (NASDAQ: SWTX) stock jumped 20% after the clinical-stage company focusing on life-changing treatment for cancer, and rar more_horizontal

SpringWorks (SWTX) Down Despite Desmoid Tumors Study Meeting Goal

By Zacks Investment Research
May 25, 2022

SpringWorks (SWTX) Down Despite Desmoid Tumors Study Meeting Goal

SpringWorks' (SWTX) phase III study evaluating its investigational candidate, nirogacestat, in adult patients with progressing desmoid tumors, meets p more_horizontal

SpringWorks Therapeutics: Rating Buy Ahead Of Mid-Year Data Releases

By Seeking Alpha
May 2, 2022

SpringWorks Therapeutics: Rating Buy Ahead Of Mid-Year Data Releases

Data from Phase 3 trial for Nirogacestat in treating desmoid tumors and Phase 2 combination trial with anti-BCMA antibody Blenrep in relapsed/refracto more_horizontal


Search within

Pages Search Results: